On January 18th, Novo Nordisk announced the main results of the Phase 3b clinical trial STEP UP on January 17th local time. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, with a weight loss of 18.7% regardless of treatment adherence. The experiment reached its primary endpoint, which was that at week 72, 7.2mg semaglutide showed statistically significant and superior weight loss compared to placebo. When all subjects were evaluated to have followed the treatment plan, starting from an average baseline weight of 113 kilograms, subjects treated with 7.2 mg semaglutide lost 20.7% of their weight after 72 weeks, while the 2.4 mg semaglutide group lost 17.5% and the placebo group lost 2.4%. In addition, 33.2% of subjects treated with 7.2mg semaglutide experienced a weight loss of 25% or more after 72 weeks, compared to 16.7% in the 2.4mg semaglutide group and 0.0% in the placebo group.
Scan code to share